Related Experiment Video

Updated: Jun 1, 2026

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation

Peter M Blumberg1, Larry V Pearce, Jeewoo Lee

  • 1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-4255, USA. blumberp@dc37a.nci.nih.gov

Current Topics in Medicinal Chemistry
|June 16, 2011
PubMed

Insights

Transient Receptor Potential Vanilloid 1 (TRPV1) is a key target for pain and other conditions. Its complex pharmacology offers diverse drug design opportunities beyond simple activation or blocking.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Discovery

Background:

  • Transient Receptor Potential Vanilloid 1 (TRPV1) is a validated therapeutic target for pain and other conditions like asthma and incontinence.
  • Resiniferatoxin, an ultrapotent TRPV1 ligand, aids in distinguishing acute activation from desensitization.
  • Medicinal chemistry efforts highlight the extensive potential for TRPV1 pharmacological manipulation.

Purpose of the Study:

  • To explore the multifaceted pharmacological landscape of TRPV1 for therapeutic development.
  • To identify novel drug design strategies beyond traditional agonism and antagonism.
  • To leverage TRPV1's complex properties for targeted therapeutic interventions.

Main Methods:

  • Analysis of TRPV1 ligand interactions, focusing on resiniferatoxin.
  • Review of medicinal chemistry approaches targeting TRPV1.
  • Examination of TRPV1's pharmacological complexity, including partial agonism/antagonism, signaling pathway modulation, desensitization kinetics, and action kinetics.

Main Results:

  • TRPV1 presents a rich area for drug development due to its complex pharmacology.
  • Beyond simple agonism and antagonism, partial agonism/antagonism offers therapeutic potential.
  • Modulation by signaling pathways, variable desensitization, and slow kinetics are exploitable features.

Conclusions:

  • The pharmacological complexity of TRPV1 provides significant opportunities for innovative drug design.
  • Exploiting partial agonism/antagonism and kinetic properties can lead to novel therapeutics.
  • TRPV1 remains a highly promising target for conditions beyond pain, including asthma and incontinence.

More Related Videos

A Simple and Inexpensive Method for Determining Cold Sensitivity and Adaptation in Mice08:35

A Simple and Inexpensive Method for Determining Cold Sensitivity and Adaptation in Mice

Published on: March 17, 2015

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
Thermosensation01:43

Thermosensation

Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Repressible Operon: trp Operon01:21

Repressible Operon: trp Operon

The trp operon in Escherichia coli exemplifies a repressible operon. It regulates the synthesis of tryptophan through repressor-mediated transcriptional control and attenuation. This dual regulatory mechanism ensures tryptophan biosynthesis occurs only when needed, conserving cellular resources.Structure of the trp OperonThe trp operon consists of five structural genes (trpE, trpD, trpC, trpB, and trpA) that encode enzymes for tryptophan biosynthesis. These genes are transcribed as a single...